Pim Mutsaers

2.2k total citations · 1 hit paper
30 papers, 371 citations indexed

About

Pim Mutsaers is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Pim Mutsaers has authored 30 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 11 papers in Pathology and Forensic Medicine and 5 papers in Surgery. Recurrent topics in Pim Mutsaers's work include CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Pim Mutsaers is often cited by papers focused on CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Pim Mutsaers collaborates with scholars based in Netherlands, United States and Germany. Pim Mutsaers's co-authors include Alessandro Crotta, Jon Arnason, Manali Kamdar, Sandrine Montheard, Scott R. Solomon, Sami Ibrahimi, Matthew A. Lunning, Alessandro Previtali, Jeremy S. Abramson and Patrick B. Johnston and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Pim Mutsaers

25 papers receiving 367 citations

Hit Papers

Lisocabtagene maraleucel as second-line therapy for large... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
    2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pim Mutsaers Netherlands 8 270 185 59 51 42 30 371
Sami Ibrahimi United States 9 277 1.0× 158 0.9× 61 1.0× 49 1.0× 41 1.0× 33 387
Alessandro Crotta United States 7 273 1.0× 121 0.7× 55 0.9× 48 0.9× 44 1.0× 26 369
Alessandro Previtali United States 7 257 1.0× 111 0.6× 76 1.3× 84 1.6× 42 1.0× 18 374
Brian Hess United States 11 452 1.7× 354 1.9× 122 2.1× 42 0.8× 40 1.0× 53 597
Christine Dehner United States 11 402 1.5× 152 0.8× 112 1.9× 88 1.7× 71 1.7× 19 520
Houston Holmes United States 12 319 1.2× 146 0.8× 119 2.0× 88 1.7× 32 0.8× 39 540
David Cohan United States 11 281 1.0× 100 0.5× 39 0.7× 55 1.1× 9 0.2× 19 485
Gloria Iacoboni Spain 16 588 2.2× 294 1.6× 111 1.9× 102 2.0× 120 2.9× 65 730
Lori A. Leslie United States 11 252 0.9× 168 0.9× 84 1.4× 61 1.2× 26 0.6× 73 412
Hien Liu United States 11 449 1.7× 153 0.8× 67 1.1× 156 3.1× 118 2.8× 62 594

Countries citing papers authored by Pim Mutsaers

Since Specialization
Citations

This map shows the geographic impact of Pim Mutsaers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pim Mutsaers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pim Mutsaers more than expected).

Fields of papers citing papers by Pim Mutsaers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pim Mutsaers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pim Mutsaers. The network helps show where Pim Mutsaers may publish in the future.

Co-authorship network of co-authors of Pim Mutsaers

This figure shows the co-authorship network connecting the top 25 collaborators of Pim Mutsaers. A scholar is included among the top collaborators of Pim Mutsaers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pim Mutsaers. Pim Mutsaers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oldenmenger, Wendy H., et al.. (2025). Experiences of Patients and Family Caregivers After Chimeric Antigen Receptor T-Cell Therapy: A Qualitative Study. Seminars in Oncology Nursing. 41(5). 151951–151951.
2.
Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465. 1 indexed citations
3.
4.
Sureda, Anna, Antonio Pinto, Hervé Ghesquières, et al.. (2024). Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial. Hematological Oncology. 43(1). e70000–e70000.
5.
Hermans, Maud A.W., et al.. (2024). Single‐center off‐label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy. SHILAP Revista de lepidopterología. 6(1). e1014–e1014. 1 indexed citations
6.
7.
Doesum, Jaap A. van, Anne M. Spanjaart, Margot Jak, et al.. (2023). Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities. Cancers. 15(22). 5443–5443. 9 indexed citations
8.
Brink, Mirian, Marjolein van der Poel, Marie José Kersten, et al.. (2022). Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 140(9). 1009–1019. 31 indexed citations
9.
Spanjaart, Anne M., Milan Kos, Pim Mutsaers, et al.. (2022). Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. JCO Oncology Practice. 19(3). e407–e416. 7 indexed citations
10.
Brink, Mirian, Marjolein van der Poel, Marie José Kersten, et al.. (2022). Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. European Journal of Cancer. 176. 100–109. 6 indexed citations
11.
Lugtenburg, Pieternella J. & Pim Mutsaers. (2022). How I treat Elderly Patients with DLBCL in the frontline setting.. Blood. 141(21). 2566–2575. 12 indexed citations
12.
Abramson, Jeremy S., Patrick B. Johnston, Manali Kamdar, et al.. (2022). Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances. 6(23). 5969–5979. 17 indexed citations
13.
Popping, Stephanie, Richard Molenkamp, Pim Mutsaers, et al.. (2021). Diminished amplification of SARS-CoV-2 ORF1ab in a commercial dual-target qRT-PCR diagnostic assay. Journal of Virological Methods. 300. 114397–114397. 5 indexed citations
14.
Mutsaers, Pim, Hayri E. Balcıoğlu, Rowan Kuiper, et al.. (2021). V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. Cancers. 13(9). 2219–2219. 12 indexed citations
15.
Mutsaers, Pim, et al.. (2021). Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate. Journal of Clinical and Translational Research. 7(6). 809–810. 2 indexed citations
16.
Kemps, Paul G., Konnie M. Hebeda, Steven T. Pals, et al.. (2020). Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation. The Journal of Pathology Clinical Research. 7(1). 10–26. 30 indexed citations
17.
Joode, Karlijn de, Johanna A.M.G. Tol, Hans M. Westgeest, et al.. (2020). LBA79 Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Annals of Oncology. 31. S1207–S1208. 3 indexed citations
18.
Mutsaers, Pim, et al.. (2010). Additional antibody suppression from rituximab added to conventional therapy in severe, refractory anti-GBM nephritis. Clinical Kidney Journal. 3(4). 421–422. 3 indexed citations
19.
Mutsaers, Pim, et al.. (2006). Acquired torticollis as the only initially presenting symptom in a child with a brainstem glioma. European Journal of Pediatrics. 166(10). 1075–1076. 3 indexed citations
20.
Fabry, Hans F. J., Pim Mutsaers, Sybren Meijer, et al.. (2004). Clinical relevance of parasternal uptake in sentinel node procedure for breast cancer. Journal of Surgical Oncology. 87(1). 13–18. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sami Ibrahimi Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Alessandro Previtali Breakdown of academic impact, for papers by Brian Hess Breakdown of academic impact, for papers by Christine Dehner Breakdown of academic impact, for papers by Houston Holmes Breakdown of academic impact, for papers by David Cohan Breakdown of academic impact, for papers by Gloria Iacoboni Breakdown of academic impact, for papers by Lori A. Leslie Breakdown of academic impact, for papers by Hien Liu
Rankless by CCL
2026